HCPCS drug code · CMS crosswalk
Octreotide Acetate J-Code / HCPCS Code
In short
CMS assigns Octreotide Acetate NDCs to 2 HCPCS codes: J2353 (per 1 mg), J2354 (per 25 mcg). Which one applies depends on the product; the table lists each NDC with its code.
Reference
- J2353
- Injection, octreotide, depot form for intramuscular injection, 1 mgBilling unit: 1 mg
- J2354
- Injection, octreotide, non-depot form for subcutaneous or intravenous injection, 25 mcgBilling unit: 25 mcg
- Labelers
- FreseniUS Kabi USA, LLC; Glenmark Pharmaceuticals Inc., USA; Heritage Pharmaceuticals Inc.; Hikma Pharmaceuticals USA Inc.; Meitheal Pharmaceuticals Inc.; Mylan Institutional LLC; Sagent Pharmaceuticals; Teva Pharmaceuticals USA, Inc.
Medicare Part B payment limit
CMS ASP fileEffective October 1, 2026 through December 31, 2026. Payment allowance limits subject to the ASP methodology are based on 2Q26 ASP data. A payment limit is not a coverage decision; the Medicare contractor decides coverage. CMS ASP pricing files
Medicare Part B payment limit
CMS ASP fileEffective October 1, 2026 through December 31, 2026. Payment allowance limits subject to the ASP methodology are based on 2Q26 ASP data. A payment limit is not a coverage decision; the Medicare contractor decides coverage. CMS ASP pricing files
Octreotide Acetate units and claim line
Enter the dose given to get the J2353 units and the NDC line for the CMS-1500 and the 837P. This builds the J2353 line; use the code page for J2354.
Enter the dose given to build the claim line.
Octreotide Acetate NDCs and billing units
From CMS’s ASP NDC–HCPCS crosswalk, effective October 1, 2026 through December 31, 2026. Billing units per package are CMS’s figures for the code’s unit.
| NDC (11-digit) | HCPCS | Labeler | Package | Billing units per package |
|---|---|---|---|---|
| 00480-9257-08 | J2353 | Teva Pharmaceuticals USA, Inc. | 1 | 10 |
| 00480-9259-08 | J2353 | Teva Pharmaceuticals USA, Inc. | 1 | 20 |
| 00480-9262-08 | J2353 | Teva Pharmaceuticals USA, Inc. | 1 | 30 |
| 67457-0756-10 | J2353 | Mylan Institutional LLC | 1 | 10 |
| 67457-0759-20 | J2353 | Mylan Institutional LLC | 1 | 20 |
| 67457-0762-30 | J2353 | Mylan Institutional LLC | 1 | 30 |
| 00641-6174-10 | J2354 | Hikma Pharmaceuticals USA Inc. | 10 × 1 | 20 |
| 00641-6175-10 | J2354 | Hikma Pharmaceuticals USA Inc. | 10 × 1 | 40 |
| 00641-6176-10 | J2354 | Hikma Pharmaceuticals USA Inc. | 10 × 1 | 200 |
| 00641-6177-01 | J2354 | Hikma Pharmaceuticals USA Inc. | 5 | 40 |
| 00641-6178-01 | J2354 | Hikma Pharmaceuticals USA Inc. | 5 | 200 |
| 23155-0685-31 | J2354 | Heritage Pharmaceuticals Inc. | 5 | 40 |
| 23155-0686-31 | J2354 | Heritage Pharmaceuticals Inc. | 5 | 200 |
| 23155-0687-41 | J2354 | Heritage Pharmaceuticals Inc. | 10 × 1 | 20 |
| 23155-0688-41 | J2354 | Heritage Pharmaceuticals Inc. | 10 × 1 | 40 |
| 23155-0689-41 | J2354 | Heritage Pharmaceuticals Inc. | 10 × 1 | 200 |
| 25021-0451-01 | J2354 | Sagent Pharmaceuticals | 10 × 1 | 20 |
| 25021-0452-01 | J2354 | Sagent Pharmaceuticals | 10 × 1 | 40 |
| 25021-0453-01 | J2354 | Sagent Pharmaceuticals | 10 × 1 | 200 |
| 25021-0454-05 | J2354 | Sagent Pharmaceuticals | 5 | 40 |
| 25021-0463-01 | J2354 | Sagent Pharmaceuticals | 10 × 1 | 20 |
| 25021-0464-01 | J2354 | Sagent Pharmaceuticals | 10 × 1 | 40 |
| 25021-0465-01 | J2354 | Sagent Pharmaceuticals | 10 × 1 | 200 |
| 25021-0466-05 | J2354 | Sagent Pharmaceuticals | 5 | 40 |
| 25021-0467-05 | J2354 | Sagent Pharmaceuticals | 5 | 200 |
| 63323-0376-01 | J2354 | FreseniUS Kabi USA, LLC | 10 × 1 | 40 |
| 63323-0376-04 | J2354 | FreseniUS Kabi USA, LLC | 10 × 1 | 40 |
| 63323-0377-01 | J2354 | FreseniUS Kabi USA, LLC | 10 × 1 | 200 |
| 63323-0377-04 | J2354 | FreseniUS Kabi USA, LLC | 10 × 1 | 200 |
| 63323-0378-05 | J2354 | FreseniUS Kabi USA, LLC | 5 | 40 |
| 63323-0379-05 | J2354 | FreseniUS Kabi USA, LLC | 5 | 200 |
| 67457-0239-01 | J2354 | Mylan Institutional LLC | 10 × 1 | 20 |
| 67457-0245-01 | J2354 | Mylan Institutional LLC | 10 × 1 | 40 |
| 67457-0246-01 | J2354 | Mylan Institutional LLC | 10 × 1 | 200 |
| 68462-0896-10 | J2354 | Glenmark Pharmaceuticals Inc., USA | 10 × 1 | 40 |
| 68462-0897-10 | J2354 | Glenmark Pharmaceuticals Inc., USA | 10 × 1 | 200 |
| 71288-0566-02 | J2354 | Meitheal Pharmaceuticals Inc. | 10 × 1 | 20 |
| 71288-0567-02 | J2354 | Meitheal Pharmaceuticals Inc. | 10 × 1 | 40 |
| 71288-0568-02 | J2354 | Meitheal Pharmaceuticals Inc. | 10 × 1 | 200 |
Octreotide Acetate: common questions
- What is the J-code for Octreotide Acetate?
- CMS assigns Octreotide Acetate NDCs to 2 HCPCS codes: J2353 (per 1 mg), J2354 (per 25 mcg). Which one applies depends on the product; the table lists each NDC with its code.
- How many J2353 billing units are in a package of Octreotide Acetate?
- CMS lists 10 to 30 billing units per package, depending on the NDC, where one unit is 1 mg. Units to report are based on the dose given, not the package.
- How many J2354 billing units are in a package of Octreotide Acetate?
- CMS lists 20 to 200 billing units per package, depending on the NDC, where one unit is 25 mcg. Units to report are based on the dose given, not the package.
- Is J2353 a CPT code?
- No. J2353 is a HCPCS Level II code from CMS for the drug itself. Giving it, for example by injection or infusion, is usually reported with a separate CPT administration code.